Navigation Links
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2010
Date:5/17/2010

INDIANAPOLIS, May 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from 57 studies at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 4 – 8, 2010, during which the company will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine HCl for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and Merck-Serono.  

Of note are two Phase II ALIMTA studies (ASCO Abstracts #7082 and #7087), which both evaluate ALIMTA plus platinum-based chemotherapy in combination with concurrent radiation therapy in patients with advanced non-small cell lung cancer (NSCLC).  Several studies evaluating GEMZAR in combination with other potential therapies are also slated for presentation at the meeting.  

"Lilly Oncology research teams around the world are committed to finding new ways to improve and prolong the lives of people living with cancer," said John H. Johnson, president of Lilly Oncology.  "We are constantly studying new uses for our established therapies and discovering new molecules – all in the hopes of changing the way we treat cancer."  

In addition to studies on marketed Lilly Oncology products, new data will also be presented at ASCO on several Lilly Oncology molecules in clinical development, namely tasisulam (an anti-cancer agent), and ImClone's ramucirumab and cixutumumab (both are IgG1 monoclonal antibodies).  

Studies of note for ALIMTA include:

  • Abstract #7082: General Poster Session: '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Maryland (PRWEB) May 20, 2013 In ... in the field of biotoxin related illnesses , announced ... the country able to advance his protocol for treating ... Patel became the third physician to achieve certification in ... Certified Physicians, able to practice the Shoemaker Protocol in ...
(Date:5/17/2013)... GA (PRWEB) May 17, 2013 Dr. ... Gynecology, and Women’s Health at the Albert Einstein College ... Oncology at the Montefiore Medical Center. He is ... Cancer Center and leads the Einstein Breast Cancer Working ... on translational breast cancer research. He also serves as ...
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis ... been reached with Switzerland -based ... anti-infective human monoclonal antibody (mAb) products, and technologies. ... mAb products for treatment of infections by common ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
Breaking Biology Technology:Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... in small, medium and ... ... BSX ) today announced CE Mark approval of its ACUITY(R),Spiral ... resynchronization therapy pacemakers, both of,which treat heart failure. The product features ...
... France, March 3 NicOx S.A.,(Euronext Paris: COX) ... studies in the United States, which will assess ... ibuprofen and naproxen,using the Ambulatory Blood Pressure Monitoring ... in duration, will together recruit a,total of around ...
... March 3 BioWa, Inc. announced today,that ... Genentech, Inc. providing,Genentech additional access to BioWa,s ... select antibodies for potential therapeutic,applications that require ... is pleased to extend this license with ...
Cached Biology Technology:Boston Scientific Announces European Approval of New Heart Failure Lead 2Boston Scientific Announces European Approval of New Heart Failure Lead 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 2NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 5BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology 2
(Date:5/17/2013)... Ill. An international team of ... structure and cell movement inside a living frog embryo ... a new method to advance biological research and the ... Northwestern University and the Karlsruher Institut fr Technologie in ... the U.S. Department of Energy,s Argonne National Laboratory, released ...
(Date:5/16/2013)... For decades, scientists have used ancient shorelines to predict the ... Markings of a high shoreline from three million years ago, ... period were thought to be evidence of a high ... This assumption has led many scientists to think that if ... they may do just the same in our modern, progressively ...
(Date:5/16/2013)... Why do so many sports players and athletes choose ... new study to be published in Psychological Science ... suggests that it may have to do with their ... scientist Daniel Farrelly of the University of Sunderland and ... color in a competitive task had higher testosterone levels ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2World's biggest ice sheets likely more stable than previously believed 2High-testosterone competitors more likely to choose red 2
... have released satellite images of vast plumes of smoke emanating ... central and western Russia. Using equipment on the European ... have analysed and released still images taken on 4, 8 ... both a true colour image and as a false colour ...
... ANN ARBOR, Mich.---University of Michigan School of Dentistry has ... may be the largest clinical study to date using genetic ... William Giannobile, professor at U-M dentistry and director of the ... Dentistry, will lead the study for U-M. "It,s ...
... a DuPont subsidiary, will lead one of 15 research ... efficiency of American homes ─ the Building America Retrofit ... U.S. Department of Energy (DOE), will receive a total ... months to deliver innovative energy efficiency strategies to the ...
Cached Biology News:Fires around Moscow: A satellite perspective 2Landmark dental school study uses genetic test to help predict gum disease 2NJIT to help lead public/private partnership to develop high-efficiency homes 2
Request Info...
Request Info...
XBP-1 (F-4)...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Biology Products: